Orchestra Biomed Holdings (OBIO)Director bought ~$2.5K

~$2.5K

Approx. value · 1,000 sh @ $2.45

108K

Holds after · shares reported

Traded

Sep 19, 2025

Filed

Sep 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 1, 2025Insider10% owner purchased ~$1.93M of OBIO shares in the open market
2. Aug 4, 2025InsiderDirector purchased ~$55K of OBIO shares in the open market
3. Aug 21, 2025InsiderDirector purchased ~$15K of OBIO shares in the open market
4. Aug 25, 2025Insider · 3 peopleInsiders: 3 purchases (~$28K)
5. Sep 19, 2025 · this disclosureInsider · Their first buy on recordDirector purchased ~$2.5K of OBIO shares in the open market

What came next

1. Oct 24, 2025Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 3 more items)
2. Nov 14, 2025InsiderDirector purchased ~$20K of OBIO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Orchestra Biomed Holdings

For Orchestra Biomed Holdings, OQRO holds 5 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OBIO page.

Other recent filings by Jason Aryeh, Director

• SEC Form 4 at Orchestra Biomed Holdings (OBIO)May 20, 2026
• SEC Form 4 at Orchestra Biomed Holdings (OBIO)May 19, 2026
• SEC Form 4 at Ligand Pharmaceuticals, Inc. (LGND)Sep 24, 2025
• SEC Form 4 at Ligand Pharmaceuticals, Inc. (LGND)Sep 24, 2025
• SEC Form 4 at Ligand Pharmaceuticals, Inc. (LGND)Sep 24, 2025

The full history of Jason Aryeh, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Orchestra Biomed Holdings

• SEC Form 4Oct 2, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Aug 28, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Aug 4, 2026

Everything OQRO holds on this company is on its OBIO page.